Nearly one in five surveyed cancer survivors reported using cannabidiol after their diagnosis, according to new research. The findings place CBD use among cancer survivors inside a growing conversation about symptom management, particularly for pain, poor sleep and emotional distress. Still, patient-reported improvement is not the same as proof from a controlled clinical trial.
Key Takeaways
- 18 percent of surveyed cancer survivors reported using CBD after diagnosis.
- Nine in 10 CBD users said symptom relief was their main reason.
- Pain, sleep difficulties and emotional distress were the most common concerns.
- More than half reported some improvement for every symptom studied.
- Nearly half eventually stopped using CBD, often because it did not help.
CBD Use Among Cancer Survivors Reaches 18 Percent
The study, published in the Journal of Palliative Medicine, surveyed 1,258 survivors across nine cancer types. Researchers from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and Mount Sinai Hospital found that 226 participants, or 18 percent, had used CBD after receiving a cancer diagnosis.
Researchers described CBD as a non-intoxicating cannabis compound, meaning it does not generally produce the high associated with THC. Among the survivors who reported CBD use, 90 percent said they took it to relieve symptoms.
Pain and Sleep Problems Were the Top Reasons
Pain was the leading reason for CBD use, reported by 55 percent of users. Difficulty sleeping followed at 47 percent, while 35 percent reported using CBD for stress, anxiety or depression. Another 18 percent used it for neuropathy, which can involve burning, tingling, numbness or weakness.
These symptoms can remain disruptive during treatment and survivorship, helping explain why some cancer survivors are interested in CBD. That interest does not prove the products are effective.
Reported Benefits Were Common, but Not Universal
More than half of the participants using CBD for a specific concern reported at least some improvement. The rate ranged from 60 percent among those using it for neuropathy to 85 percent among the smaller group using it for low energy or fatigue.
Those results are encouraging from a patient-experience standpoint, but the study also revealed an important limitation. Nearly 47 percent of CBD users eventually stopped taking it. Among those who stopped, the most common explanation was that it did not help.
Why the Study Does Not Prove CBD Works
This was a survey, not a randomized clinical trial. Participants described their own experiences, researchers did not compare standardized doses against a placebo, and the products may have differed in strength, ingredients and quality. Because of those limits, the study cannot establish that CBD caused the reported improvements or identify the safest dose or most useful product type.
The researchers said clinical trials are still needed to evaluate CBD’s safety and effectiveness for pain, sleep problems, emotional distress and neuropathy.
CBD should not replace oncology care or prescribed treatment. Patients should discuss its use with their medical team because it may cause side effects or interact with medications.
CBD Use Among Cancer Survivors Points to a Communication Gap
The study found that younger survivors and people with brain or gastrointestinal cancers were more likely to report CBD use in initial analyses. More research is needed to understand why those differences appeared.
Open, nonjudgmental conversations can help doctors understand what products patients are using, why they are using them and whether they are experiencing side effects or medication conflicts. They may also help patients separate early research from exaggerated marketing claims, especially because CBD products can vary in dosing and quality.
Conclusion
CBD use among cancer survivors is no longer unusual. In this study, almost one in five respondents had tried it after diagnosis, usually for pain, sleep trouble or emotional distress. Many reported some improvement, but nearly half eventually stopped using it. The findings support better patient-provider conversations and more clinical research, not conclusions that CBD is proven to relieve these symptoms.
